Hanna van Waart1, Wim H van Harten1, Laurien M Buffart2, Gabe S Sonke3, Martijn M Stuiver4, Neil K Aaronson1. 1. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Physical Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: Only between 25% and 50% of patients invited to participate in clinical trial-based physical exercise programs during cancer treatment agree to do so. The purpose of this study was to identify factors associated significantly with the decision (not) to participate in a randomized controlled trial of physical exercise during adjuvant chemotherapy for breast cancer. METHODS: Based on questionnaire data, we compared trial participants and non-participants on a range of sociodemographic, clinical health-related, practical, behavioral, and attitudinal variables. RESULTS:Two hundred thirty of 524 patients agreed to participate in the trial (44%). The 294 (56%) non-participants indicated that they wanted to exercise on their own or that they did not wish to exercise in the context of a trial. Those who preferred to exercise on their own were relatively similar to trial participants but were more likely to be in the maintenance exercise stage. Those non-participants who did not wish to exercise had a significantly lower level of education, were less likely to be working, reported more fatigue and lower health-related quality of life, had lower sense of self-efficacy, more negative attitudes towards exercise, less social support, and perceived fewer benefits and more barriers to exercising during treatment than trial participants. CONCLUSION: Minimizing practical barriers to participation, providing educational materials on the potential benefits of exercise, and giving adequate professional and social network encouragement may increase the number of patients willing to exercise during treatment and to participate in such studies.
RCT Entities:
OBJECTIVE: Only between 25% and 50% of patients invited to participate in clinical trial-based physical exercise programs during cancer treatment agree to do so. The purpose of this study was to identify factors associated significantly with the decision (not) to participate in a randomized controlled trial of physical exercise during adjuvant chemotherapy for breast cancer. METHODS: Based on questionnaire data, we compared trial participants and non-participants on a range of sociodemographic, clinical health-related, practical, behavioral, and attitudinal variables. RESULTS: Two hundred thirty of 524 patients agreed to participate in the trial (44%). The 294 (56%) non-participants indicated that they wanted to exercise on their own or that they did not wish to exercise in the context of a trial. Those who preferred to exercise on their own were relatively similar to trial participants but were more likely to be in the maintenance exercise stage. Those non-participants who did not wish to exercise had a significantly lower level of education, were less likely to be working, reported more fatigue and lower health-related quality of life, had lower sense of self-efficacy, more negative attitudes towards exercise, less social support, and perceived fewer benefits and more barriers to exercising during treatment than trial participants. CONCLUSION: Minimizing practical barriers to participation, providing educational materials on the potential benefits of exercise, and giving adequate professional and social network encouragement may increase the number of patients willing to exercise during treatment and to participate in such studies.
Authors: Jennifer Huberty; Ryan Eckert; Krisstina Gowin; Jules Mitchell; Amylou C Dueck; Brenda F Ginos; Linda Larkey; Ruben Mesa Journal: Haematologica Date: 2017-06-08 Impact factor: 9.941
Authors: Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Marianne de Maaker-Berkhof; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Simone M van den Heiligenberg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson Journal: Int J Colorectal Dis Date: 2017-11-09 Impact factor: 2.571
Authors: Sally A D Romero; Lee Jones; Joshua M Bauml; Q Susan Li; Roger B Cohen; Jun J Mao Journal: Support Care Cancer Date: 2018-04-19 Impact factor: 3.603
Authors: Hanna van Waart; Laurien M Buffart; Martijn M Stuiver; Wim H van Harten; Gabe S Sonke; Neil K Aaronson Journal: Support Care Cancer Date: 2019-08-08 Impact factor: 3.603
Authors: Heather S L Jim; Aasha I Hoogland; Hyo Sook Han; Eva Culakova; Charles Heckler; Michelle Janelsins; Geoffrey C Williams; Julienne Bower; Stephen Cole; Zeruesenay Desta; Margarita Bobonis Babilonia; Gary Morrow; Luke Peppone Journal: Contemp Clin Trials Date: 2020-03-05 Impact factor: 2.226
Authors: Laurien M Buffart; Maike G Sweegers; Anne M May; Mai J Chinapaw; Jonna K van Vulpen; Rob U Newton; Daniel A Galvão; Neil K Aaronson; Martijn M Stuiver; Paul B Jacobsen; Irma M Verdonck-de Leeuw; Karen Steindorf; Melinda L Irwin; Sandi Hayes; Kathleen A Griffith; Alejandro Lucia; Fernando Herrero-Roman; Ilse Mesters; Ellen van Weert; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Gill Arbane; Martina E Schmidt; Karin Potthoff; Marc van Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H van Harten; Rachel Garrod; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem van Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Johannes Brug; Kerry S Courneya Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Jennifer Y Sheng; Dipali Sharma; Gerald Jerome; Cesar Augusto Santa-Maria Journal: Oncology (Williston Park) Date: 2018-08-15 Impact factor: 2.533